Category: Medical Devices

Thrive: What’s the first thing you do when you get out of bed?

Lisa Jewell: Check my phone. I go to my email first, and then the news, but if either of my teenage daughters were out when I fell asleep, I go straight to SnapMaps to check that they are home.

Thrive: What gives you energy?

LJ: I always tend to have just enough energy for what I need to do. I tick over at an even keel all day long, I don’t tend to dip up and down.

Thrive: What’s your secret life hack?

LJ: I make

By Landry Signé

Secretary of State Antony Blinken and his team will be in sub-Saharan Africa from August 7 to 12, paying visits to three countries: South Africa, the Democratic Republic of the Congo (DRC), and Rwanda. The visit comes at a critical time given the global pandemic and the war in Ukraine, which has profoundly impacted the entire continent of Africa. Overall, Blinken’s goal is to build on his visit of last November and foster closer relations between African countries and the United States—to accelerate progress on mutual interests so that both sides can flourish together within a complex global

By Landry Signé

Secretary of State Antony Blinken and his team will be in sub-Saharan Africa from August 7 to 12, paying visits to three countries: South Africa, the Democratic Republic of the Congo (DRC), and Rwanda. The visit comes at a critical time given the global pandemic and the war in Ukraine, which has profoundly impacted the entire continent of Africa. Overall, Blinken’s goal is to build on his visit of last November and foster closer relations between African countries and the United States—to accelerate progress on mutual interests so that both sides can flourish together within a complex global

By Vanda Felbab-Brown

The successful U.S. hit against Ayman al-Zawahri, the post-Osama bin Laden leader of al-Qaida, is a great moment of justice: Zawahri had been a key plotter of 9/11 and other vicious terrorist attacks. Although in recent years he has not been involved in daily tactical al-Qaida planning, his death will have a negative strategic and demoralizing impact on al-Qaida. Al-Qaida will not stop existing and operating, but it has again been put on the back foot.

This impressive show of the effectiveness and persistence of U.S. counterterrorism efforts is also an important demonstration to the world — and

In an episode of the “All Else Equal” podcast series from Stanford Graduate School of Business, Wharton’s Jules van Binsbergen and Stanford’s Jonathan Berk discuss the strategies available to the social-minded investor, and why they are not clear-cut.…Read More

By Justin Damien Guénette

The Russian Federation’s invasion of Ukraine was yet another supply shock to a global economy still reeling from the consequences of the COVID-19 pandemic. According to the June 2022 edition of the Global Economic Prospects report, global growth is projected to slow sharply from 5.7 percent in 2021 to 2.9 percent this year (Figure 1). The effects of the invasion account for most of the 1.2 percentage point downward revision to this year’s global growth forecast. Growth in emerging market and developing economies (EMDEs) is expected to slow from 6.6 percent in 2021 to 3.4 percent in

By Justin Damien Guénette

The Russian Federation’s invasion of Ukraine was yet another supply shock to a global economy still reeling from the consequences of the COVID-19 pandemic. According to the June 2022 edition of the Global Economic Prospects report, global growth is projected to slow sharply from 5.7 percent in 2021 to 2.9 percent this year (Figure 1). The effects of the invasion account for most of the 1.2 percentage point downward revision to this year’s global growth forecast. Growth in emerging market and developing economies (EMDEs) is expected to slow from 6.6 percent in 2021 to 3.4 percent in

If you’re struggling to manage a hybrid team or workforce, start by understanding five key challenges, says Wharton’s Martine Haas in this Nano Tool for Leaders. …Read More

The Minneapolis Federal Reserve’s moves to shape state education policy have triggered a broader debate on central bank activism. Wharton’s Christina Parajon Skinner weighs in.…Read More

As Mirati Therapeutics waits for the Food and Drug Administration to complete a review of its KRAS-targeting lung cancer drug later this year, final results from a clinical trial reported Thursday could both help and hinder the biotech’s efforts to stand apart from a rival Amgen treatment approved one year ago.

In its own clinical trial, the Mirati drug, called adagrasib, shrank tumors in 43% of patients with advanced lung cancer — a result that tops the 37% response rate from a study reported by Amgen for its drug, called Lumakras.

Continue to STAT+ to read the full story…